Company Drug

CMS Secures NMPA Approval for Desidustat – First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market

By Fineline Cube #China Medical System #HKG: 0867 #Product approvals
CMS Secures NMPA Approval for Desidustat – First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market

China Medical System Holdings (CMS; HKG: 0867) announced marketing approval from China’s National Medical Products Administration (NMPA) for desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in adult chronic kidney disease (CKD) patients without dialysis. The approval, based on successful Phase III data demonstrating sustained hemoglobin control and favorable long-term safety, positions CMS to capture share in China’s expanding renal anemia market.

Regulatory Milestone

ItemDetail
AgencyNMPA (China)
Approval TypeMarketing authorization (Category 1 innovative drug)
ProductDesidustat (oral HIF-PHI)
DeveloperChina Medical System Holdings (CMS; HKG: 0867)
IndicationAnemia in adult CKD patients not on dialysis
SignificanceFirst domestically developed HIF-PHI approved in China

Clinical Evidence

EndpointPhase III ResultClinical Impact
Primary EfficacyMet primary endpointNon-inferior/superior Hb elevation vs. standard of care
Long-Term Hb MaintenanceSustained target Hb levels during extension periodReduced transfusion burden; improved quality of life
Hepcidin ReductionSignificant decrease in hepcidin levelsAddresses functional iron deficiency—key CKD anemia driver
Iron MetabolismCorrection of iron metabolism disordersEnhanced iron availability for erythropoiesis
Safety ProfileFavorable long-term tolerabilitySupports chronic outpatient administration

Product Profile & Market Position

AttributeDesidustat Specification
MechanismHIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitor)
RouteOral (convenient vs. injectable ESAs)
Target Population~50 million non-dialysis CKD patients in China; ~40% anemic
DifferentiationOral dosing + iron metabolism correction vs. erythropoiesis-stimulating agents (ESAs) and IV iron

Competitive Landscape:

  • Roxadustat (Fibrogen/AstraZeneca): First HIF-PHI approved in China (2018); established market presence
  • Daprodustat (GSK): Approved 2023; once-daily dosing
  • Desidustat Positioning: Domestic innovation with potential cost advantage and formulary preference under “Buy China” policies

Market Impact & Commercial Outlook

FactorImplication
CKD Anemia MarketChina RMB 8–10 billion annually; shifting from ESAs to HIF-PHIs driven by oral convenience and cardiovascular safety data
NRDL StrategyNDA filing supports 2026 NRDL negotiation; inclusion critical for volume access in public hospitals
Physician AdoptionNephrology preference for HIF-PHIs growing; desidustat offers alternative to roxadustat with differentiated iron metabolism profile
Revenue ForecastPeak sales RMB 500–800 million annually assuming 10–15% non-dialysis CKD anemia market share
  • Manufacturing: CMS to leverage internal formulation capacity; API sourcing secured through domestic suppliers
  • Pipeline Synergy: Validates CMS renal franchise; potential for dialysis indication expansion and combination with phosphate binders

Forward‑Looking Statements
This brief contains forward‑looking statements regarding NRDL inclusion timelines, market penetration, and competitive positioning for desidustat. Actual results may differ due to reimbursement negotiations, physician prescribing patterns, and safety surveillance outcomes in real-world use.-Fineline Info & Tech

Related Post

Company Deals

Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets

Fineline Cube
Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Fineline Cube
Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Fineline Cube

You Missed

Company Deals

Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets

Company Drug

CMS Secures NMPA Approval for Desidustat – First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market

Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market